AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 107-114

  Mongelard, Fabien ^a   Bouvet, Philippe ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; AS 1411; BEVACIZUMAB; CYTARABINE; DOXORUBICIN; GEMCITABINE; INTERFERON; INTERLEUKIN 2; NUCLEOLIN; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; FEBRILE NEUTROPENIA; HEMANGIOPERICYTOMA; HUMAN; HYBRIDIZATION; HYPOKALEMIA; HYPOMAGNESEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE HELIX; TUMOR CELL; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

MUS;

EID: 76749169748     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Antiproliferative activity of G-rich oligonucleotides correlates with protein-binding. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM J BIOL CHEM 1999 274 37 26369-26377
2. Aptamera and Archemix announce product development and license agreement for AGRO100 for the treatment of cancer. Aptamera Inc PRESS RELEASE 2003 August 14
3. Pre-clinical efficacy, pharmacokinetic, and toxicity studies of AGRO100, an anti-tumor oligonucleotide aptamer. Barnhart KM, Bates PJ, Trent JO, Xu X, Thomas S, Miller DM PROC AM ASSOC CANCER RES 2004 45 876
4. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK J Biol Chem 2004 279 12 10855-10863
5. A phase I study of AGRO100 in advanced cancer. Laber DA, Choudry MA, Taft BS, Bhupalam L, Sharma VR, Hendler FJ, Barnhart KM PROC AM SOC CLIN ONCOL 2004 23 Abs 3112
6. AGRO100: The translation from lab to clinic of a tumortargeted nucleic acid aptamer. Barnhart KM, Laber DA, Bates PJ, Trent JO, Miller DM PROC AM SOC CLIN ONCOL 2004 23 Abs 3126
7. Antisoma and Raylo sign major manufacturing deal for AS1411. Antisoma plc PRESS RELEASE 2005 March 14
8. Promising phase I data for Antisoma's AS1411 revealed at ASCO Antisoma plans to reopen study in renal and lung cancers. Antisoma plc Press Release 2005 May 16
9. Update on the first phase I study of AGRO100 in advanced cancer. Laber DA, Sharma VR, Bhupalam L, Taft B, Hendler FJ, Barnhart KM PROC AM SOC CLIN ONCOL 2005 24 Abs 3064
10. First patient treated in extended phase I trial of Antisoma's AS1411. Antisoma plc Press Release 2005 September 06
11. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Takagi M, Absalon MJ, McLure KG, Kastan MB Cell 2005 123 1 49-63
12. Extended follow-up of renal cancer patients provides new support for Antisoma's AS1411. Antisoma plc Press Release 2005 November 16
13. Preclinical anticancer properties of a G-rich oligonucleotidebased aptamer, AS1411. Ireson C, Djeha H, Cook J, Ritchie C, Jones D, Green C, Trent J, Bates P, Miller D, Kelland L Clin Cancer Res 2005 11 24 9114S-9114S
14. Long term clinical responses in renal cell carcinoma patients treated with quadriplex forming oligonucleotides. Laber D, Bates P, Trent J, Barnhart K, Taft B, Miller DM AACR NCI EORTC MOL TARGETS CANCER THER 2005 11 24 B228
15. Cancer cell kill, in vivo biodistribution and antitumor properties of AS1411, a G-rich oligonucleotide aptamer. Ireson C, Green C, Cook J, Djeha H, Ritchie C, Jones D, Kelland LR PROC AM ASSOC CANCER RES 2006 47 1107-1108
16. A role for protein arginine methyltransferase 5 (PRMT5) in the mechanism of novel anticancer agent, AS1411. Teng Y, Bates PJ PROC AM ASSOC CANCER RES 2006 47 1295
17. Second dramatic response seen with Antisoma's AS1411 in renal cancer. Antisoma plc Press Release 2006 September 05
18. Antisoma announces positive phase I data on AS1411, plans phase II trials in renal and blood cancers. Antisoma plc Press Release 2006 October 02
19. AS1411, a novel DNA aptamer as a potential treatment of acute myelogenous leukaemia (AML). Shah K, Djeha H, Richie C, McGeever G, Green C Blood 2006 108 11 Abs 1996
20. Proteomic studies of nucleolin complexes in prostate cancer cells treated with novel anticancer agent, AS1411. Teng Y, Pierce WM Jr, Bates PJ AM ASSOC CANCER RES ANN MEET 2007 98 Abs 3275
21. Uncoupling of cell growth and division: An unusual mechanism of non-apoptotic cell death in leukemia cells treated with novel anticancer aptamer, AS1411. Soleimani-Meigooni DN, Mi Y, Thomas SD, Jenson AB, Bates PJ AM ASSOC CANCER RES ANN MEET 2007 98 Abs 1924
22. Antisoma starts phase II trial of AS1411 in acute myeloid leukaemia. Antisoma plc PRESS RELEASE 2007 August 06
23. Pharmacokinetics of the anti-nucleolin aptamer AS1411 in a phase I study. Laber A, Taft S, Kloecker H, Acton, Miller M AACR-NCIEORTC INT CONGRESS 2007 19 Abs C147
24. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Shi HB, Huang YJ, Zhou H, Song XM, Yuan SP, Fu Y, Luo YZ Blood 2007 110 8 2899-2906
25. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Teng Y, Girvan AC, Casson LK, Pierce WM, Qian N, Thomas SD, Bates PJ Cancer Res 2007 67 21 10491-10500
26. Activity and mechanism of action of AS1411 in acute myeloid leukemia cells. Chen W, Sridharan V, Soundararajan S, Otake Y, Stuart R, Jones D, Fernandes D AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 Abs 1604
27. ImmuPharma enters oncology with novel potential blockbuster drug for multiple cancer indications. ImmuPharma Ltd PRESS RELEASE 2008 January 09
28. The nucleolin targeting aptamer AS1411 destabilizes bcl-2 messenger RNA in human breast cancer cells. Soundararajan S, Chen WW, Spicer EK, Courtenay-Luck N, Fernandes DJ CANCER RES 2008 68 7 2358-2365
29. AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs in vitro and in vivo in AML models. Jones D, Dobinson D, Doran B, Odumeru T, Shah K, Kuijper S, Green C, Courtenay-Luck N, McLaughlin F, Djeha H AM ASSOC CANCER RES ANN MEET 2008 99 Abs 5689
30. Early findings show promise as AS1411 AML study proceeds to higher-dose stage. Antisoma plc Press Release 2008 July 07
31. Relapsed and refractory acute myeloid leukemia (AML) treated with AS1411 and cytarabine: A randomized phase II trial Stuart RK, Acton G AM SOC HEMATOL ANN MEET EXPOSITION 2008 50 Abs 1935
32. Antisoma announces positive interim data from AS1411 phase II trial in acute myeloid leukaemia. Antisoma plc Press Release 2008 December 08
33. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Wang L, Sridharan V, Soundararajan S, Stuart R, McLaughlin F, Courtenay-Luck N, Fernandes D AM ASSOC CANCER RES ANN MEET 2009 100 Abs 5846
34. Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). Stuart RK, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D AM SOC CLIN ONCOL ANN MEET 2009 45 Abs 7019
35. Extended phase I study of AS1411 in renal and non-small cell lung cancers. Miller DM, Laber DA, Bates PJ, Trent JO, Taft BS, Kloecker GH Ann Oncol 2006 17 147-148
36. AGRO100 inhibits activation of nuclear factor-ß B (NF-ßB) by forming a complex with NF-ßB essential modulator (NEMO) and nucleolin. Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, Klein JB, Pierce WM, Barve SS, Bates PJ MOL CANCER THER 2006 5 7 1790-1799
37. AS1411 in combination with cytarabine in relapsed and refractory acute myeloid leukemia. Stuart K, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D HAEMATOLOGICA-HEMATOL J 2009 94 Suppl 2 336
38. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Soundararajan S, Wang L, Sridharan V, Chen WW, Courtenay-Luck N, Jones D, Spicer EK, Fernandes DJ Mol Pharmacol 2009 76 5 984-991
39. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO EXP MOL PATHOL2009 86 3 151-164
40. Discovery and development of anticancer aptamers. Ireson CR, Kelland LR Molec ular Cancer Therape utics 2006 5 12 2957-2962
41. Combination of the aptamer AS1411 with paclitaxel or Ara-C produces synergistic inhibition of cancer cell growth. Ritchie C, Doran B, Shah K, Djeha H, Dobinson D, Rowlinson-Busza G, Courtenay-Luck N, Green C, Jones D PROC AM ASSOC CANCER RES 2007 48 Abs 4818
42. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Dapic V, Abdomerovic V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ Nucleic Acids Res 2003 31 8 2097-2107
43. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM Biochemistr y 2002 41 11 3676-3685
44. G-rich oligonucleotides for cancer treatment. Bates PJ, Choi EW, Nayak LV METHODS MOL BIOL 2009 542 379-392
45. Functions of the histone chaperone nucleolin in diseases. Storck S, Shukla M, Dimitrov S, Bouvet P Subcell Biochem 2007 41 125-144
46. Molecular dissection of nucleolin's role in growth and cell proliferation: New insights. Srivastava M, Pollard HB FASEB J 1999 13 14 1911-1922
47. Nucleolin: A multifunctional major nucleolar phosphoprotein. Tuteja R, Tuteja N CRIT REV BIOCHEM MOL BIOL 1998 33 6 407-436
48. Nucleolin: A multifaceted protein. Mongelard F, Bouvet P Trends Cell Biol 2007 17 2 80-86
49. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. Xu XH, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ J BIOL CHEM 2001 276 46 43221-43230
50. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ Blood 2007 109 7 3069-3075
51. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Scoumanne A, Zhang J, Chen X NUCLEIC ACIDS RES 2009 37 15 4965-4976
52. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Wang L, Pal S, Sif S Mol Cell Biol 2008 28 20 6262-6277
53. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Saxena A, Rorie CJ, Dimitrov D, Daniely Y, Borowiec JA Oncogene 2006 25 55 7274-7288
54. Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. Daniely Y, Dimitrova DD, Borowiec JA Mol CELL BIOL 2002 22 16 6014-6022
55. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E J CELL BIOL 2003 163 4 871-878
56. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y Blood 2006 107 9 3564-3571
57. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG PLoS ONE 2008 3 6 e2518
58. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Fogal V, Sugahara KN, Ruoslahti E, Christian S ANGIOGENESIS 2009 12 1 91-100
59. Extended phase I study of AS1411 in renal and non-small cell lung cancers. Laber DA, Taft BS, Kloecker GH, Bates PJ, Trent JO, Miller DM J Clin Oncol 2006 24 18S Abs 13098
60. Activity and mechanism of action of the anti-cancer aptamer AS1411 through regulation of Bcl-2 family members. Kuijper S, Doran B, Ritchie C, Lu YC, Djeha H, McLaughlin F, Jones D AACR NCI EORTC MOL TARGETS CANCER THER 2008 20 PO
61. Aptamers: A new class of oligonucleotides in the drug discovery pipeline? Dausse E, Da Rocha Gomes S, Toulmé JJ CURR OPIN PHARMACOL 2009 9 5 602-607
62. Antisoma discontinues AS-1411 development for renal cell carcinoma. Antisoma plc PRESS RELEASE 2009 December 16